McKesson Reports Q1 2027 Sales and Profit Growth Amid Outlook Raise

McKesson MCK reported fiscal 2027 first-quarter results with consolidated revenue of $105.4 billion, up 8% year over year, and raised its full-year adjusted earnings-per-share guidance on the back of the print.

The update matters because McKesson is the largest US drug distributor, and its specialty pharmaceuticals business has become the main growth engine as traditional generic-distribution margins stay thin. North American pharmaceutical revenue surged 19%, powered largely by demand for specialty and oncology drugs that carry fatter margins than commodity generics.

Gross profit grew faster than revenue in the quarter, a sign the specialty and oncology mix shift is doing more work than volume alone. The earnings beat and margin strength led McKesson to lift its outlook for the rest of fiscal 2027.

Investors will be watching whether the specialty pharmaceuticals momentum holds through the next few quarters and whether McKesson can keep expanding margins as it leans further into higher-value drug categories. The raised guidance suggests management expects the trend to continue, though durability could hinge on payer reimbursement policy and competition in specialty drug distribution.

Related Stocks

• MCK